[Clinical studies of dibekacin intravenous challenge on respiratory tract infections (author's transl)].

Abstract

Dibekacin was used for the treatment of 5 patients with bacterial respiratory tract infections (4 cases of Ps. aeruginosa and 1 case of S. marcescens) intravenously. Serum levels of DKB was observed by the method of enzyme immunoassay (EIA) and bioassay and no differentiation was observed between EIA and bioassay. Four cases of Ps. aeruginosa and 1 case of S. marcescens were all disappeared in 5 or 7 days of administration. No side effects were observed. The results obtained in this study indicate that DKB intravenous challenge might become one of the important method on respiratory tract infections.

• Authors: I Hayashi, H Okamoto
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 34 Issue 7 Pg. 1098-105 (Jul 1981) ISSN: 0368-2781 [Print] Japan
• PMID: 7321189 (Publication Type: English Abstract, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Dibekacin
• Kanamycin

Topics

• Adolescent
• Adult
• Aged
• Anti-Bacterial Agents (metabolism, therapeutic use)
• Dibekacin (administration & dosage, metabolism)
• Drug Evaluation
• Female
• Humans
• Infusions, Parenteral
• Kanamycin (analogs & derivatives)
• Male
• Middle Aged
• Pseudomonas Infections (drug therapy)
• Respiratory Tract Infections (drug therapy, microbiology)
• Sputum (metabolism)